Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It ...

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...

A new study highlights that the experimental blood-thinner abelacimab significantly reduces bleeding risks in atrial fibrillation patients compared to standard treatments like rivaroxaban. In trial ...

That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation system in a larger group of patients with atrial fibrillation.

The researchers found that just six weeks of anabolic steroid use can harm the way cells in the heart work together. The ...